感染

订阅

MedSci主页 / 所有栏目 / 感染

SCI REP：脓毒症患者短期和长期认知变化的相关因素！

2018-03-14 xing.T MedSci原创

脓毒症短期长期认知变化因素
关注

一般来说，严重脓毒症或感染性休克患者存在的认知障碍可随着时间的推移而改善。这种改善与他们的ICU停留期间的因素有关，如认知储备、教育水平、在ICU停留期间的平均血糖以及NSE水平。

近日，Scientific reports杂志上发表了一篇研究文章，研究人员的目的是评估严重脓毒症或感染性休克患者的认知情况，以及明确认知功能障碍是否与临床和实验室参数有关。

研究人员对严重败血症和感染性休克患者进行了一项队列研究，在24 h内以及ICU出院后一年进行评估分析。研究人员对受试者人口统计学指标、临床和实验室数据进行了分析，并进行以下神经心理学测验：CERAD、简易精神状态评估以及A型和B型的试路试验。

研究人员纳入了33名患者，平均年龄为49岁，19%为女性。患者在ICU出院后24小时进行了大多数指标测定，随访可以改善。ICU出院时IQCODE、APACHE II评分、NSE和IFN-γ水平均与认知表现较差相关，而较高的教育水平与良好的认知功能有关。首次抗生素治疗时间、ICU停留期间累积的氟哌啶醇剂量及平均血糖也与较差的认知预后有关。

一般来说，严重脓毒症或感染性休克患者存在的认知障碍可随着时间的推移而改善。这种改善与他们的ICU停留期间的因素有关，如认知储备、教育水平、在ICU停留期间的平均血糖以及NSE水平。

原始出处：

Allan J. C. Calsavara,et al. Factors Associated With Short and Long Term Cognitive Changes in Patients With Sepsis.Scientific reports.2018. https://www.nature.com/articles/s41598-018-22754-3

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1812853, encodeId=653c181285367, content=<a href='/topic/show?id=9a0a91225d8' target=_blank style='color:#2F92EE;'>#认知变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91225, encryptionId=9a0a91225d8, topicName=认知变化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 04 16:27:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301500, encodeId=458230150054, content=非常好.多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:48 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301499, encodeId=8eb330149913, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:26 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457484, encodeId=94b5145e48483, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516363, encodeId=e8da15163639b, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-06-04 仁心济世

    #认知变化#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1812853, encodeId=653c181285367, content=<a href='/topic/show?id=9a0a91225d8' target=_blank style='color:#2F92EE;'>#认知变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91225, encryptionId=9a0a91225d8, topicName=认知变化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 04 16:27:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301500, encodeId=458230150054, content=非常好.多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:48 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301499, encodeId=8eb330149913, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:26 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457484, encodeId=94b5145e48483, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516363, encodeId=e8da15163639b, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-31 马路1平

    非常好.多谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1812853, encodeId=653c181285367, content=<a href='/topic/show?id=9a0a91225d8' target=_blank style='color:#2F92EE;'>#认知变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91225, encryptionId=9a0a91225d8, topicName=认知变化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 04 16:27:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301500, encodeId=458230150054, content=非常好.多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:48 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301499, encodeId=8eb330149913, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:26 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457484, encodeId=94b5145e48483, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516363, encodeId=e8da15163639b, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-31 马路1平

    已读

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1812853, encodeId=653c181285367, content=<a href='/topic/show?id=9a0a91225d8' target=_blank style='color:#2F92EE;'>#认知变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91225, encryptionId=9a0a91225d8, topicName=认知变化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 04 16:27:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301500, encodeId=458230150054, content=非常好.多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:48 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301499, encodeId=8eb330149913, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:26 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457484, encodeId=94b5145e48483, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516363, encodeId=e8da15163639b, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-16 zzc2213

    #相关因素#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1812853, encodeId=653c181285367, content=<a href='/topic/show?id=9a0a91225d8' target=_blank style='color:#2F92EE;'>#认知变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91225, encryptionId=9a0a91225d8, topicName=认知变化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 04 16:27:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301500, encodeId=458230150054, content=非常好.多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:48 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301499, encodeId=8eb330149913, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlnMA4Mv0JEd3wqGB7GHzs1MsciccMzuKz0NRuK1DznR2t4OvibiaIxQF4BD7icaXxtmRtVzoRjzbSbQ/0, createdBy=11672154424, createdName=马路1平, createdTime=Sat Mar 31 14:09:26 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457484, encodeId=94b5145e48483, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516363, encodeId=e8da15163639b, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Fri Mar 16 11:27:00 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-16 dlwang_26703130

    #脓毒症患者#

    0

相关资讯

Blood:CD19 CAR-T疗法引发脓毒症 随意使用如同与虎谋皮？

近年来，过继性CAR-T细胞免疫疗法作为一种针对多种癌症的新型疗法，其前景似乎不可限量。2017年8月30日，美国食品和药物管理局（FDA）批准了首个基因疗法产品（一种自体CD19 CAR-T产品）开启了癌症治疗的新篇章。尽管不同CD19 CAR-T产品带来的缓解效果令人鼓舞，但是诸如细胞因子释放综合征（CRS）和神经毒性之类的并发症引起越来越多的关注。

Crit Care：美罗培南在脓毒症患者持续低效透析中的药代动力学研究！

近期，一项发表在杂志Crit Care上的研究旨在描述在接受持续低效透析（SLED）的重症患者中美罗培南的群体药代动力学（PK）。此项研究招募了19例接受美罗培南和SLED治疗的急性肾损伤败血症患者。在SLED之前、之中和之后，每个患者进行三次连续血液样品检测以评估美罗培南浓度。使用蒙特卡洛模拟的非参数群体进行PK分析。使用最小抑菌浓度（f T> MIC）的40％和100％时间的药效学（PD

Curr Opin Crit Care：重视脓毒症患者的体格检查

监护重症患者的过程中，我们可以通过无创手段来完成对患者意识状态和外周循环变化的监测。值得我们注意的是，体格检查可以替代性地评估临床治疗的短期疗效，所以应重视不同临床背景下（如脓毒症）对患者进行常规的体格监测。脓毒症相关性脑病的发生或意识状态的改变与患者不良预后具有相关性，评估脓毒性休克患者的外周循环状态是预测其临床预后的一项实用易行且准确的监测方法。基于最新相关研究结果，本文目的在于强调对脓毒症患

Ann Intensive Care：他汀类药物治疗对ICU脓毒症患者的宿主反应有影响吗？

2018年，发表在《Ann Intensive Care》上的一项前瞻性观察研究，考察了他汀类药物治疗对重症脓毒症患者宿主反应的影响情况。

Crit Care Med：红细胞输注对脓毒症患者有哪些不良影响？

2017年12月，发表于《Crit Care Med》上的一项使用边际结构Cox模型的观察性研究，考察了红细胞输注不会影响重度脓毒症患者的总体死亡率，但ICU获得性感染和严重低氧血症的发生率将增加。

日本脓毒症和脓毒性休克的管理指南

日本脓毒症和脓毒性休克的管理指南由日本重症监护医学学会(JSICM)联合日本急诊医学协会(JAAM)制定。全文共针对19个临床领域提出了87个临床问题，涉及儿科领域以及其他第一版指南未涉及的重要领域。